@SethRBauer next up on vasopressor choice after norepinephrine (NE) failure- #CHEST2024 NE dose at which vasopressin should be started @gretchensacha ‘s paper https://t.co/ImnO1NP4C3 Vasopressin response: arterial PH and NE dose https://t.co/wnUHdlzCRg Cardiac function and

Don’t miss out on downloading this great article before it goes behind the paywall

My current thinking is: 1️⃣We should consider angiotensin II for this rationale particularly if renin is “high” ( https://t.co/FLjBpcZbNv) 2️⃣🤷🏻‍♂️ but we probably should be titrating vasopressin and treating it as a vasopressor, not “endocrine replacement”😜 What do you think?

This has me pondering for shock: 1️⃣Why do we use exogenous vasopressin for a “relative deficiency” but not angiotensin II for the same rationale? 2️⃣If we use angiotensin II for a “relative deficiency” why do we titrate the dosage instead of using a fixed dosage like vasopressin?

Framing I didn’t previously consider (inspired by @pwierusz): When the kidneys sense hypoperfusion they release renin to activate the RAS. Since the downstream effect of renin is to increase angiotensin II, the kidneys interpret hypoperfusion as a deficiency of angiotensin II.

Thinking about vasopressor verbiage in light of a recent discussion with @pwierusz. Our thinking is aligned but I’m curious about your opinion. If a patient is on norepinephrine, vasopressin is added, then norepinephrine titrated off, is the vasopressin adjunctive or monotherapy?

Thanks @lisa_burry! Poster can be reviewed/downloaded with the link below. Stay tuned for the manuscript - in peer review now.

This article from the Mayo pharmacy group (co-authored by @erin_barreto and @pwierusz) is downright amazing. 🔥 They have accomplished incredible things! After reading I immediately sent to our team as a model to emulate.

🚨NEW POD ALERT🚨 🧂Norepinephrine Position Paper & Sepsis Research Priorities 🥇 Ft. Brittany Bissell Turpin @BissellTurpin Patrick Wieruszewski @pwierusz @mayoanesthesia @curiousboxwood Seth Bauer @SethRBauer History of norepinephrine formulation reporting 📜 Clinical &

Check out this new, comprehensive guideline on albumin use.👇🏻 TL;dr: Few indications where albumin use can be recommended (or even suggested). It was a huge honor for me to work with and learn from this international group of expert methodologists, researchers, and clinicians.

It was such a pleasure to be invited to speak about my journey into research with the @umsop faculty. I’m very appreciate of Dr. @HeavnerPharmD’s invitation. 🙏🏻

Original research suggests that implementing a protocol for peripheral administration of norepinephrine safely can avoid 1 central venous catheter day in the average patient. Read more in the February @journal_CHEST issue: https://t.co/ZIu7rKYzwI #MedTwitter #MedEd #CritCare

Our preliminary work on Forecasting disease trajectories in critical illness using probabilistic dynamic systems is out @AbhiDuggalMD @RScheraga @gretchensacha @msiuba @emireles_c @SethRBauer @siddharth_dugar @SimonMuchaMD

Huge congrats to @gretchensacha on being inducted as a fellow in ACCM. Well deserved recognition. #SCCM24

I’m so grateful to be able to chat with this group of outstanding pharmacist-scientists about problems few understand, but each of these folks have experienced and overcome.

An outstanding presentation by @SheilaMyatra on the new SSC Research Priorities document. Check out the paper 👇🏻 https://t.co/8iu7txkZap

#SCCM2024 #SCCMSoMe @SheilaMyatra talking about research priorities in sepsis. https://t.co/uALsIE5iEG

It was exciting to hear the fascinating work firsthand from @iamyourgasman and his team. Check out the link to their paper 👇🏻

https://t.co/GRDgnQRWNU

And if you’re anywhere in the realm of #sepsis #septicshock #vasopressors #catecholamines #priorities then you would not want to miss @ESICM @SCCM joint session @skanegill @criticcaredoc we can’t wait to share what we have learnt with the world! @SOCCA_CritCare